ZA200308544B - Imidazo[1,5-a]pyrimido[5,4-d]benzazepine derivatives as GABA A receptor modulators. - Google Patents
Imidazo[1,5-a]pyrimido[5,4-d]benzazepine derivatives as GABA A receptor modulators. Download PDFInfo
- Publication number
- ZA200308544B ZA200308544B ZA200308544A ZA200308544A ZA200308544B ZA 200308544 B ZA200308544 B ZA 200308544B ZA 200308544 A ZA200308544 A ZA 200308544A ZA 200308544 A ZA200308544 A ZA 200308544A ZA 200308544 B ZA200308544 B ZA 200308544B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- benzazepine
- pyrimido
- imidazo
- Prior art date
Links
- 102000004300 GABA-A Receptors Human genes 0.000 title description 12
- 108090000839 GABA-A Receptors Proteins 0.000 title description 12
- RZBORXKBSMHCCE-UHFFFAOYSA-N 2,4,10,12-tetrazatetracyclo[12.4.0.02,6.08,13]octadeca-1(18),4,6,8,10,12,14,16-octaene Chemical class C=1C2=CN=CN=C2C2=CC=CC=C2N2CN=CC2=1 RZBORXKBSMHCCE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 34
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 13
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- JZYGPQZLNIDLPD-UHFFFAOYSA-N ethyl 17-fluoro-3-propan-2-yl-2,4,10,12-tetrazatetracyclo[12.4.0.02,6.08,13]octadeca-1(14),3,5,8(13),9,11,15,17-octaene-9-carboxylate Chemical compound C(C)OC(=O)C=1N=CN=C2C=1CC=1N(C3=C2C=CC(=C3)F)C(=NC=1)C(C)C JZYGPQZLNIDLPD-UHFFFAOYSA-N 0.000 claims description 2
- MWCWRHMRAJIUNY-UHFFFAOYSA-N ethyl 3-cyclopropyl-17-fluoro-2,4,10,12-tetrazatetracyclo[12.4.0.02,6.08,13]octadeca-1(14),3,5,8(13),9,11,15,17-octaene-9-carboxylate Chemical compound C(C)OC(=O)C=1N=CN=C2C=1CC=1N(C3=C2C=CC(=C3)F)C(=NC=1)C1CC1 MWCWRHMRAJIUNY-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 2
- SSRIYPPJKDWTLD-UHFFFAOYSA-N 10-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6-methyl-9h-imidazo[1,5-a]pyrimido[5,4-d][1]benzazepine Chemical compound CC1=NCN(C=23)C1=CC1=CN=CN=C1C3=CC=CC=2C(ON=1)=NC=1C1CC1 SSRIYPPJKDWTLD-UHFFFAOYSA-N 0.000 claims 1
- 102100028651 Tenascin-N Human genes 0.000 claims 1
- 101710087911 Tenascin-N Proteins 0.000 claims 1
- 239000007787 solid Substances 0.000 description 64
- 239000000243 solution Substances 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- HEGOGQZKFXNZBM-UHFFFAOYSA-N 7-chloro-4-(dimethylaminomethylidene)-1h-1-benzazepine-2,5-dione Chemical compound O=C1C(=CN(C)C)CC(=O)NC2=CC=C(Cl)C=C21 HEGOGQZKFXNZBM-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- -1 for example Chemical group 0.000 description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 6
- YQOZAYAIFDRKAO-UHFFFAOYSA-N 4-(dimethylaminomethylidene)-1h-1-benzazepine-2,5-dione Chemical compound O=C1C(=CN(C)C)CC(=O)NC2=CC=CC=C21 YQOZAYAIFDRKAO-UHFFFAOYSA-N 0.000 description 5
- YZZFLLQDSQPMPN-UHFFFAOYSA-N 4-(dimethylaminomethylidene)-7-fluoro-1h-1-benzazepine-2,5-dione Chemical compound O=C1C(=CN(C)C)CC(=O)NC2=CC=C(F)C=C21 YZZFLLQDSQPMPN-UHFFFAOYSA-N 0.000 description 5
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- JRYOZJIRAVZGMV-UHFFFAOYSA-N cyclopropanecarboximidamide;hydron;chloride Chemical compound Cl.NC(=N)C1CC1 JRYOZJIRAVZGMV-UHFFFAOYSA-N 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- VWXLCWNPSOUPPE-UHFFFAOYSA-N (1-amino-2-methylpropylidene)azanium;chloride Chemical compound Cl.CC(C)C(N)=N VWXLCWNPSOUPPE-UHFFFAOYSA-N 0.000 description 3
- ARDGQYVTLGUJII-UHFFFAOYSA-N 2,2-dimethylpropanimidamide;hydrochloride Chemical compound Cl.CC(C)(C)C(N)=N ARDGQYVTLGUJII-UHFFFAOYSA-N 0.000 description 3
- GXFFJBLDPMTOJJ-UHFFFAOYSA-N 2-(1h-indol-3-yl)ethanimidamide Chemical compound C1=CC=C2C(CC(=N)N)=CNC2=C1 GXFFJBLDPMTOJJ-UHFFFAOYSA-N 0.000 description 3
- LOJFRHBZDMXJPA-UHFFFAOYSA-N 2-(4-methoxyphenyl)ethanimidamide;hydrochloride Chemical compound Cl.COC1=CC=C(CC(N)=N)C=C1 LOJFRHBZDMXJPA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- JSYGRUBHOCKMGQ-UHFFFAOYSA-N dichloramine Chemical compound ClNCl JSYGRUBHOCKMGQ-UHFFFAOYSA-N 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- AZVWIMLQRLKLHH-UHFFFAOYSA-N (5-methyl-1,2-oxazol-3-yl)methanamine Chemical compound CC1=CC(CN)=NO1 AZVWIMLQRLKLHH-UHFFFAOYSA-N 0.000 description 2
- GHBKKPSEJBPINY-UHFFFAOYSA-N 10-chloro-2-propan-2-yl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=C(Cl)C=C2C2=NC(C(C)C)=NC=C21 GHBKKPSEJBPINY-UHFFFAOYSA-N 0.000 description 2
- CIVZHVZUMZYFJP-UHFFFAOYSA-N 1h-1-benzazepine-2,5-dione Chemical compound N1C(=O)C=CC(=O)C2=CC=CC=C21 CIVZHVZUMZYFJP-UHFFFAOYSA-N 0.000 description 2
- UGCFWOLFLKDSCX-UHFFFAOYSA-N 2-cyclopropyl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound N1=C2C3=CC=CC=C3NC(=O)CC2=CN=C1C1CC1 UGCFWOLFLKDSCX-UHFFFAOYSA-N 0.000 description 2
- XFKCVVFQGHCLIP-UHFFFAOYSA-N 2-ethylbutanedioyl dichloride Chemical compound CCC(C(Cl)=O)CC(Cl)=O XFKCVVFQGHCLIP-UHFFFAOYSA-N 0.000 description 2
- MNNJPFJBFUARCI-UHFFFAOYSA-N 2-propyl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=CC=C2C2=NC(CCC)=NC=C21 MNNJPFJBFUARCI-UHFFFAOYSA-N 0.000 description 2
- RWJOVJVWIVBYKF-UHFFFAOYSA-N 3-(azidomethyl)-5-methyl-1,2-oxazole Chemical compound CC1=CC(CN=[N+]=[N-])=NO1 RWJOVJVWIVBYKF-UHFFFAOYSA-N 0.000 description 2
- ASGJFGPILHALRC-UHFFFAOYSA-N 3-(bromomethyl)-5-methyl-1,2-oxazole Chemical compound CC1=CC(CBr)=NO1 ASGJFGPILHALRC-UHFFFAOYSA-N 0.000 description 2
- SFVCOZOGYYJPII-UHFFFAOYSA-N 7-bromo-4-(dimethylaminomethylidene)-1h-1-benzazepine-2,5-dione Chemical compound O=C1C(=CN(C)C)CC(=O)NC2=CC=C(Br)C=C21 SFVCOZOGYYJPII-UHFFFAOYSA-N 0.000 description 2
- YRUGIDNPYWLNBV-UHFFFAOYSA-N 7-chloro-3,4-dihydro-1h-1-benzazepine-2,5-dione Chemical compound N1C(=O)CCC(=O)C2=CC(Cl)=CC=C21 YRUGIDNPYWLNBV-UHFFFAOYSA-N 0.000 description 2
- JLWCRRWZBRCFDJ-UHFFFAOYSA-N 7-fluoro-3,4-dihydro-1h-1-benzazepine-2,5-dione Chemical compound N1C(=O)CCC(=O)C2=CC(F)=CC=C21 JLWCRRWZBRCFDJ-UHFFFAOYSA-N 0.000 description 2
- 229940084657 Benzodiazepine receptor inverse agonist Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- TWLLPUMZVVGILS-UHFFFAOYSA-N Ethyl 2-aminobenzoate Chemical compound CCOC(=O)C1=CC=CC=C1N TWLLPUMZVVGILS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- STYCVEYASXULRN-UHFFFAOYSA-N butanimidamide;hydrochloride Chemical compound [Cl-].CCCC(N)=[NH2+] STYCVEYASXULRN-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- PKWFESSNWKEZDP-UHFFFAOYSA-N ethyl 2-amino-5-bromobenzoate Chemical compound CCOC(=O)C1=CC(Br)=CC=C1N PKWFESSNWKEZDP-UHFFFAOYSA-N 0.000 description 2
- XWWBMLMEVRIPSX-UHFFFAOYSA-N ethyl 2-amino-5-chlorobenzoate Chemical compound CCOC(=O)C1=CC(Cl)=CC=C1N XWWBMLMEVRIPSX-UHFFFAOYSA-N 0.000 description 2
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 2
- JDEXFODYDIAIDM-UHFFFAOYSA-N ethyl 7-bromo-5-hydroxy-2-oxo-1,3-dihydro-1-benzazepine-4-carboxylate Chemical compound N1C(=O)CC(C(=O)OCC)=C(O)C2=CC(Br)=CC=C21 JDEXFODYDIAIDM-UHFFFAOYSA-N 0.000 description 2
- OGAJQLVXLWNPBQ-UHFFFAOYSA-N ethyl 7-chloro-5-hydroxy-2-oxo-1,3-dihydro-1-benzazepine-4-carboxylate Chemical compound N1C(=O)CC(C(=O)OCC)=C(O)C2=CC(Cl)=CC=C21 OGAJQLVXLWNPBQ-UHFFFAOYSA-N 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- MFUVDXOKPBAHMC-UHFFFAOYSA-N magnesium;dinitrate;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MFUVDXOKPBAHMC-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- GYVGXEWAOAAJEU-UHFFFAOYSA-N n,n,4-trimethylaniline Chemical compound CN(C)C1=CC=C(C)C=C1 GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000000216 proconvulsive effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- MDYHWQQHEWDJKR-UHFFFAOYSA-N (5-methyl-1,2-oxazol-3-yl)methanol Chemical compound CC1=CC(CO)=NO1 MDYHWQQHEWDJKR-UHFFFAOYSA-N 0.000 description 1
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 description 1
- OCUSYBHPZIFMRI-UHFFFAOYSA-N 1-benzazepin-6-one Chemical compound N1=CC=CC=C2C(=O)C=CC=C21 OCUSYBHPZIFMRI-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- VJCKESJFSQDYPK-UHFFFAOYSA-N 10-bromo-2-methyl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=C(Br)C=C2C2=NC(C)=NC=C21 VJCKESJFSQDYPK-UHFFFAOYSA-N 0.000 description 1
- ZMLSAYFUYICYSA-UHFFFAOYSA-N 10-bromo-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound N1C(=O)CC2=CN=CN=C2C2=CC(Br)=CC=C21 ZMLSAYFUYICYSA-UHFFFAOYSA-N 0.000 description 1
- UVNZDKMESCNYGA-UHFFFAOYSA-N 10-chloro-2-cyclopropyl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound N1=C2C3=CC(Cl)=CC=C3NC(=O)CC2=CN=C1C1CC1 UVNZDKMESCNYGA-UHFFFAOYSA-N 0.000 description 1
- FBNCXUFOEYIGHJ-UHFFFAOYSA-N 10-chloro-2-methyl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=C(Cl)C=C2C2=NC(C)=NC=C21 FBNCXUFOEYIGHJ-UHFFFAOYSA-N 0.000 description 1
- DVOFZQFFSNACDD-UHFFFAOYSA-N 10-fluoro-2-(1h-indol-3-ylmethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound N1=C2C3=CC(F)=CC=C3NC(=O)CC2=CN=C1CC1=CNC2=CC=CC=C12 DVOFZQFFSNACDD-UHFFFAOYSA-N 0.000 description 1
- HPDCYKAGSWBSCB-UHFFFAOYSA-N 10-fluoro-2-[(4-methoxyphenyl)methyl]-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1=CC(OC)=CC=C1CC1=NC=C(CC(=O)NC=2C3=CC(F)=CC=2)C3=N1 HPDCYKAGSWBSCB-UHFFFAOYSA-N 0.000 description 1
- ZYKHDYHESBDKIL-UHFFFAOYSA-N 10-fluoro-2-methyl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=C(F)C=C2C2=NC(C)=NC=C21 ZYKHDYHESBDKIL-UHFFFAOYSA-N 0.000 description 1
- HDFDLOSCTUYTKC-UHFFFAOYSA-N 10-fluoro-2-propan-2-yl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=C(F)C=C2C2=NC(C(C)C)=NC=C21 HDFDLOSCTUYTKC-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- IPGINVKCFFJJKB-UHFFFAOYSA-N 2-(1h-indol-3-ylmethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound N1=C2C3=CC=CC=C3NC(=O)CC2=CN=C1CC1=CNC2=CC=CC=C12 IPGINVKCFFJJKB-UHFFFAOYSA-N 0.000 description 1
- CUKXRHLWPSBCTI-UHFFFAOYSA-N 2-amino-5-bromobenzoic acid Chemical compound NC1=CC=C(Br)C=C1C(O)=O CUKXRHLWPSBCTI-UHFFFAOYSA-N 0.000 description 1
- CKZXJWRRHLEBCD-UHFFFAOYSA-N 2-propan-2-yl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=CC=C2C2=NC(C(C)C)=NC=C21 CKZXJWRRHLEBCD-UHFFFAOYSA-N 0.000 description 1
- UNHOVIPXYDEGAP-UHFFFAOYSA-N 2-tert-butyl-10-chloro-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=C(Cl)C=C2C2=NC(C(C)(C)C)=NC=C21 UNHOVIPXYDEGAP-UHFFFAOYSA-N 0.000 description 1
- AZEJQGKRGWUVTK-UHFFFAOYSA-N 2-tert-butyl-10-fluoro-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=C(F)C=C2C2=NC(C(C)(C)C)=NC=C21 AZEJQGKRGWUVTK-UHFFFAOYSA-N 0.000 description 1
- ZSJPNQKUGABWCF-UHFFFAOYSA-N 2-tert-butyl-5,7-dihydropyrimido[5,4-d][1]benzazepin-6-one Chemical compound C1C(=O)NC2=CC=CC=C2C2=NC(C(C)(C)C)=NC=C21 ZSJPNQKUGABWCF-UHFFFAOYSA-N 0.000 description 1
- VDTXDALRBZEUFV-UHFFFAOYSA-N 3,4-dihydro-1h-1-benzazepine-2,5-dione Chemical compound N1C(=O)CCC(=O)C2=CC=CC=C21 VDTXDALRBZEUFV-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FPQMGQZTBWIHDN-UHFFFAOYSA-N 5-fluoroanthranilic acid Chemical compound NC1=CC=C(F)C=C1C(O)=O FPQMGQZTBWIHDN-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- AUDMZFAMLPFLHP-UHFFFAOYSA-N 6-methyl-9h-imidazo[1,5-a]pyrimido[5,4-d][1]benzazepine-10-carboxylic acid ethyl ester Chemical compound C12=NC=NC=C2C=C2C(C)=NCN2C2=C1C=CC=C2C(=O)OCC AUDMZFAMLPFLHP-UHFFFAOYSA-N 0.000 description 1
- XSSMUNSMBSUOAW-UHFFFAOYSA-N 7-bromo-3,4-dihydro-1h-1-benzazepine-2,5-dione Chemical compound N1C(=O)CCC(=O)C2=CC(Br)=CC=C21 XSSMUNSMBSUOAW-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MRROPEWAOJXNFB-GQCTYLIASA-N CN(C)\C=N\CC(O)=O Chemical compound CN(C)\C=N\CC(O)=O MRROPEWAOJXNFB-GQCTYLIASA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000017934 GABA-B receptor Human genes 0.000 description 1
- 108060003377 GABA-B receptor Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical class SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- IWHAHQVFMZOWQJ-UHFFFAOYSA-N ethyl 17-bromo-2,4,10,12-tetrazatetracyclo[12.4.0.02,6.08,13]octadeca-1(14),3,5,8(13),9,11,15,17-octaene-9-carboxylate Chemical compound C(C)OC(=O)C=1N=CN=C2C=1CC=1N(C3=C2C=CC(=C3)Br)C=NC=1 IWHAHQVFMZOWQJ-UHFFFAOYSA-N 0.000 description 1
- WEKFWCFKWGUMPB-UHFFFAOYSA-N ethyl 17-bromo-3-methyl-2,4,10,12-tetrazatetracyclo[12.4.0.02,6.08,13]octadeca-1(14),3,5,8(13),9,11,15,17-octaene-9-carboxylate Chemical compound C(C)OC(=O)C=1N=CN=C2C=1CC=1N(C3=C2C=CC(=C3)Br)C(=NC=1)C WEKFWCFKWGUMPB-UHFFFAOYSA-N 0.000 description 1
- MPNDLCMUUIQRJI-UHFFFAOYSA-N ethyl 17-chloro-3-cyclopropyl-2,4,10,12-tetrazatetracyclo[12.4.0.02,6.08,13]octadeca-1(14),3,5,8(13),9,11,15,17-octaene-9-carboxylate Chemical compound C(C)OC(=O)C=1N=CN=C2C=1CC=1N(C3=C2C=CC(=C3)Cl)C(=NC=1)C1CC1 MPNDLCMUUIQRJI-UHFFFAOYSA-N 0.000 description 1
- MPKHPDXNGHDQSL-UHFFFAOYSA-N ethyl 2,4,10,12-tetrazatetracyclo[12.4.0.02,6.08,13]octadeca-1(18),3,5,8(13),9,11,14,16-octaene-9-carboxylate Chemical compound C(C)OC(=O)C=1N=CN=C2C=1CC=1N(C3=C2C=CC=C3)C=NC=1 MPKHPDXNGHDQSL-UHFFFAOYSA-N 0.000 description 1
- OYQVQWIASIXXRT-UHFFFAOYSA-N ethyl 2,4-dioxopentanoate Chemical compound CCOC(=O)C(=O)CC(C)=O OYQVQWIASIXXRT-UHFFFAOYSA-N 0.000 description 1
- JXVAFPULGWAWJD-UHFFFAOYSA-N ethyl 2-(dimethylaminomethylideneamino)acetate Chemical compound CCOC(=O)CN=CN(C)C JXVAFPULGWAWJD-UHFFFAOYSA-N 0.000 description 1
- HSKOREORSSOUOG-UHFFFAOYSA-N ethyl 2-amino-5-fluorobenzoate Chemical compound CCOC(=O)C1=CC(F)=CC=C1N HSKOREORSSOUOG-UHFFFAOYSA-N 0.000 description 1
- MZDOALRUOUWDRL-UHFFFAOYSA-N ethyl 2-aminobenzoate;2-(ethylamino)benzoic acid Chemical compound CCNC1=CC=CC=C1C(O)=O.CCOC(=O)C1=CC=CC=C1N MZDOALRUOUWDRL-UHFFFAOYSA-N 0.000 description 1
- ADMQMZVVXJWKOH-UHFFFAOYSA-N ethyl 7-fluoro-5-hydroxy-2-oxo-1,3-dihydro-1-benzazepine-4-carboxylate Chemical compound N1C(=O)CC(C(=O)OCC)=C(O)C2=CC(F)=CC=C21 ADMQMZVVXJWKOH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- YFKAOVPMZLHAFC-UHFFFAOYSA-N n,n-dimethyl-1,1-bis(methylperoxy)methanamine Chemical compound COOC(N(C)C)OOC YFKAOVPMZLHAFC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112222 | 2001-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200308544B true ZA200308544B (en) | 2005-01-31 |
Family
ID=8177471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200308544A ZA200308544B (en) | 2001-05-18 | 2003-10-31 | Imidazo[1,5-a]pyrimido[5,4-d]benzazepine derivatives as GABA A receptor modulators. |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6686352B2 (bg) |
| EP (1) | EP1399448B1 (bg) |
| JP (1) | JP4068466B2 (bg) |
| KR (1) | KR100533406B1 (bg) |
| CN (1) | CN1230436C (bg) |
| AR (1) | AR033753A1 (bg) |
| AT (1) | ATE283857T1 (bg) |
| AU (1) | AU2002338898B2 (bg) |
| BG (1) | BG108369A (bg) |
| BR (1) | BR0209859A (bg) |
| CA (1) | CA2446903C (bg) |
| CZ (1) | CZ20033355A3 (bg) |
| DE (1) | DE60202147T2 (bg) |
| DK (1) | DK1399448T3 (bg) |
| EC (1) | ECSP034851A (bg) |
| ES (1) | ES2232778T3 (bg) |
| GT (1) | GT200200087A (bg) |
| HK (1) | HK1066544A1 (bg) |
| HR (1) | HRP20030890A2 (bg) |
| HU (1) | HUP0400743A3 (bg) |
| IL (2) | IL158572A0 (bg) |
| JO (1) | JO2297B1 (bg) |
| MA (1) | MA27024A1 (bg) |
| MX (1) | MXPA03010529A (bg) |
| MY (1) | MY127570A (bg) |
| NO (1) | NO20035104L (bg) |
| NZ (1) | NZ529097A (bg) |
| PA (1) | PA8545201A1 (bg) |
| PE (1) | PE20030041A1 (bg) |
| PL (1) | PL366846A1 (bg) |
| PT (1) | PT1399448E (bg) |
| RU (1) | RU2287531C2 (bg) |
| SI (1) | SI1399448T1 (bg) |
| SK (1) | SK15252003A3 (bg) |
| TW (1) | TWI251489B (bg) |
| WO (1) | WO2002094834A1 (bg) |
| YU (1) | YU90003A (bg) |
| ZA (1) | ZA200308544B (bg) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE381566T1 (de) | 2004-05-14 | 2008-01-15 | Millennium Pharm Inc | Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase |
| AU2005294575B2 (en) * | 2004-10-04 | 2011-11-24 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
| CA2584757C (en) * | 2004-10-20 | 2012-07-03 | F. Hoffmann-La Roche Ag | Halogen substituted benzodiazepine derivatives |
| RU2007112940A (ru) * | 2004-10-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные имидазобензодиазепина |
| CN101287738B (zh) * | 2005-10-11 | 2011-08-10 | 弗·哈夫曼-拉罗切有限公司 | 咪唑并苯并二氮杂*衍生物 |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| CL2008003749A1 (es) | 2007-12-17 | 2010-01-15 | Janssen Pharmaceutica Nv | Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras. |
| CN101735211B (zh) * | 2008-11-04 | 2012-11-14 | 复旦大学 | 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途 |
| AR074487A1 (es) * | 2008-12-05 | 2011-01-19 | Millennium Pharm Inc | Tiolactamas inhibidoras de proteinquinasas plk, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de trastornos proliferativos e inflamatorios, en particular cancer. |
| WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| CA2788774A1 (en) | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
| CN101891706B (zh) * | 2010-04-09 | 2013-05-29 | 复旦大学 | 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途 |
| CN102424670A (zh) * | 2011-10-31 | 2012-04-25 | 江苏阿尔法药业有限公司 | 一种合成3-(3-氯丙基)-1,3,4,5-四氢-7,8-二甲氧基-2h-3-苯并氮杂卓-2-酮的方法 |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| US9724354B2 (en) | 2013-03-22 | 2017-08-08 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase |
| MX2016007808A (es) | 2013-12-20 | 2016-09-07 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo. |
| CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2019246300A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN110452172B (zh) * | 2019-08-21 | 2021-03-26 | 爱斯特（成都）生物制药股份有限公司 | 一种苯并己内酰胺的合成方法 |
| CN112159411A (zh) * | 2020-10-15 | 2021-01-01 | 南京工业大学 | 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201311B (bg) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| FR2783828B1 (fr) | 1998-09-29 | 2000-11-10 | Synthelabo | Derives d'acide 5,6-dihydro-4h-imidazo[1,2-a][1] benzazepine -1-acetique, leur preparation et leur application en therapeutique |
| AU1481701A (en) | 1999-11-12 | 2001-06-06 | Neurogen Corporation | Bicyclic and tricyclic heteroaromatic compounds |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
-
2002
- 2002-04-09 US US10/118,584 patent/US6686352B2/en not_active Expired - Fee Related
- 2002-05-08 RU RU2003136078/04A patent/RU2287531C2/ru not_active IP Right Cessation
- 2002-05-08 ES ES02771640T patent/ES2232778T3/es not_active Expired - Lifetime
- 2002-05-08 PT PT02771640T patent/PT1399448E/pt unknown
- 2002-05-08 CZ CZ20033355A patent/CZ20033355A3/cs unknown
- 2002-05-08 JP JP2002591507A patent/JP4068466B2/ja not_active Expired - Fee Related
- 2002-05-08 HU HU0400743A patent/HUP0400743A3/hu unknown
- 2002-05-08 BR BR0209859-8A patent/BR0209859A/pt not_active IP Right Cessation
- 2002-05-08 PL PL02366846A patent/PL366846A1/xx not_active Application Discontinuation
- 2002-05-08 MX MXPA03010529A patent/MXPA03010529A/es active IP Right Grant
- 2002-05-08 NZ NZ529097A patent/NZ529097A/en unknown
- 2002-05-08 IL IL15857202A patent/IL158572A0/xx unknown
- 2002-05-08 EP EP02771640A patent/EP1399448B1/en not_active Expired - Lifetime
- 2002-05-08 KR KR10-2003-7015036A patent/KR100533406B1/ko not_active IP Right Cessation
- 2002-05-08 AU AU2002338898A patent/AU2002338898B2/en not_active Ceased
- 2002-05-08 SI SI200230055T patent/SI1399448T1/xx unknown
- 2002-05-08 CA CA002446903A patent/CA2446903C/en not_active Expired - Fee Related
- 2002-05-08 SK SK1525-2003A patent/SK15252003A3/sk unknown
- 2002-05-08 AT AT02771640T patent/ATE283857T1/de not_active IP Right Cessation
- 2002-05-08 DK DK02771640T patent/DK1399448T3/da active
- 2002-05-08 WO PCT/EP2002/005121 patent/WO2002094834A1/en active IP Right Grant
- 2002-05-08 CN CNB028101774A patent/CN1230436C/zh not_active Expired - Fee Related
- 2002-05-08 DE DE60202147T patent/DE60202147T2/de not_active Expired - Lifetime
- 2002-05-08 YU YU90003A patent/YU90003A/sh unknown
- 2002-05-14 JO JO200243A patent/JO2297B1/en active
- 2002-05-15 TW TW091110162A patent/TWI251489B/zh not_active IP Right Cessation
- 2002-05-15 PA PA20028545201A patent/PA8545201A1/es unknown
- 2002-05-16 PE PE2002000413A patent/PE20030041A1/es not_active Application Discontinuation
- 2002-05-16 GT GT200200087A patent/GT200200087A/es unknown
- 2002-05-16 AR ARP020101805A patent/AR033753A1/es not_active Application Discontinuation
- 2002-05-17 MY MYPI20021808A patent/MY127570A/en unknown
-
2003
- 2003-10-23 IL IL158572A patent/IL158572A/en not_active IP Right Cessation
- 2003-10-31 ZA ZA200308544A patent/ZA200308544B/en unknown
- 2003-11-04 HR HR20030890A patent/HRP20030890A2/xx not_active Application Discontinuation
- 2003-11-14 MA MA27398A patent/MA27024A1/fr unknown
- 2003-11-17 NO NO20035104A patent/NO20035104L/no not_active Application Discontinuation
- 2003-11-17 EC EC2003004851A patent/ECSP034851A/es unknown
- 2003-11-18 BG BG108369A patent/BG108369A/bg unknown
-
2004
- 2004-12-01 HK HK04109492A patent/HK1066544A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200308544B (en) | Imidazo[1,5-a]pyrimido[5,4-d]benzazepine derivatives as GABA A receptor modulators. | |
| AU2002338898A1 (en) | Imidazo [1,5-A] pyrimido [5,4-D] benzazepine derivatives as GABA A receptor modulators | |
| AU2002217007B2 (en) | Benzodiazepine derivatives as GABA A receptor modulators | |
| EP1765829B1 (en) | Tricyclic compounds and their use as mglur1 antagonists | |
| RU2139873C1 (ru) | Имидазодиазепины, способ их получения и лекарственное средство | |
| AU2005272584B2 (en) | Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase I epsilon | |
| AU2002217007A1 (en) | Benzodiazepine derivatives as GABA A receptor modulators | |
| JP2003146987A (ja) | ２−アリールプリン−９−アセトアミド誘導体 | |
| CA2069382A1 (en) | Imidazodiazepine | |
| IE862575L (en) | e-FUSED-(1,2,4) TRIAZOLO (1,5-c) PYRIMIDINES | |
| ES2244065T3 (es) | Derivados de 5-sustituido-3-oxadiazolil-1,6-naftiridin-2(1h)-ona. | |
| WO2006108773A1 (en) | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | |
| CA2210631C (en) | Tricyclic benzazepine vasopressin antagonists | |
| JPH0710874A (ja) | ３−（１，２，４−オキサジアゾリル）−５，６，７，８−テトラヒドロ−１，６−ナフチリジン誘導体 |